COVID-19: Vaccine as good in ‘real world’ as in trial in Israel

More data from Israel’s vaccination program is suggesting the Pfizer jab prevents 94% of symptomatic infections.

This indicates the vaccine is performing just as well in a larger population as it did in the clinical trials.

It is proving highly effective at preventing illness and severe disease among all age groups, according to public health doctor Professor Hagai Levine.

“High vaccination coverage of the most susceptible groups” was key, he said.

Israel’s largest health fund Clalit looked at positive tests in 600,000 vaccinated people and the same number of unvaccinated people, matched by age and health status. It found 94% fewer infections among the vaccinated group.

This was based on test results in people’s medical records, usually taken if they had symptoms or were a close contact of someone who had tested positive. And the vaccine prevented almost all cases of serious illness. This pattern was the same in all age groups.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.